Proteomic plasma biomarkers for predicting response and resistance with immune checkpoint inhibitors in cancer patients

In this study, Olink Proteomics demonstrates how comprehensive proteomic profiling can enable the discovery of important immune and tumor changes associated with response or non-response to checkpoint blockade, and how plasma-based biomarkers can allow the identification of baseline predictive biomarkers for response to immunotherapy.